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Essentials
• The risk factors for infection in immune thrombocytopenia are not well known.
• We conducted a national pharmacoepidemiological study.
• Pulmonary disease, corticosteroids and rituximab were the main risk factors for infections.
• Pneumococcal and influenza vaccines were protective against infections.
Summary. Introduction: Risk factors for infection and protective effect of vaccines in immune thrombocytopenia (ITP) patients in the era of rituximab therapy are unknown. Objectives: To assess the risk factors for serious and non-serious infections (respectively, SIs and NSIs) in non-splenectomized adults treated for persistent or chronic primary ITP, including the effect of pneumococcal and influenza vaccines. Patients/Methods: The population was the 2009-2012 FAITH cohort (n = 1805), which is the cohort of all incident (newly diagnosed) primary ITP adults treated > 3 months in France built into the national health insurance database (SNIIRAM). SIs were hospitalizations with any infection as the primary diagnosis code. NSIs were identified using out-of-hospital antibiotic dispensing. Cox models were performed. Results: Incidence rates were 6.3/100 patientyears (95% confidence interval [CI], 5.4-7.4) for SIs (lower respiratory tract in 42.8% of the cases) and 100.5/ 100 patient-years (95% CI, 95.0-106.3) for NSIs. In multivariate analyses, increasing age and chronic pulmonary disease were associated with both SI and NSI occurrence. The hazard ratios (HRs) for corticosteroids and rituximab were, respectively, 3.83 (95% CI 
Introduction
Immune thrombocytopenia (ITP) is a bleeding disorder that occurs because of an autoimmune reaction directed against platelets and megakaryocytes [1]. It is described as 'primary' when not associated with another disease (about 80% of adult ITPs) [1] . First-line treatment is based on corticosteroids [2, 3] . In the case of severe bleeding, intravenous polyvalent immunoglobulins (IVIg) are added [4] . In adults, about 70% of ITPs become persistent (lasting ≥ 3 months) or chronic (lasting ≥ 12 months) [1, [5] [6] [7] . In these cases, several treatments can be used as corticosteroid-sparing agents. Splenectomy is the reference treatment [3] , which has a response rate of 60% after a median follow-up of 20 years [8] . However, many other drugs are frequently used before splenectomy as a result of the patient's or physician's reluctance to undertake this definitive, surgical treatment [9] . Among these drugs, rituximab, a monoclonal antibody directed against CD20, has been used off-label since the 2000s. It was the leading non-corticosteroid treatment used during the persistency phase in France between 2009 and 2011 [10] . IVIg and immunosuppressants such as azathioprine, mycophenolate and cyclosporine are less frequently used [3, 10] .
Several population-based studies have demonstrated an increased risk of infection in ITP patients as compared with the general population [11, 12] . Mortality as a result of infection seems also to be increased in ITP [13, 14] . Splenectomy is a well-known risk factor for infection, including in ITP patients [12, [15] [16] [17] .
However, little is known about other risk factors for infection in ITP patients. In particular, data about the risk of infection associated with other ITP treatments such as corticosteroids or rituximab in the real-life setting are scarce [18] [19] [20] . Among potential protective factors, the effect of influenza and pneumococcal vaccines has not been assessed, although ITP patients treated with immunomodulatory drugs are eligible for these according to French guidelines on vaccination [21] .
The aim of this study was to assess the risk factors for serious and non-serious infections, and the effect of pneumococcal and influenza vaccines, in non-splenectomized adults treated for a persistent or chronic primary ITP.
Methods
This observational study was carried out in the so-called FAITH (French Adult Immune Thrombocytopenia: a French Pharmacoepidemiological Study) cohort. This cohort is registered in the post-authorization survey registry of the European Network Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) coordinated by the European Medicine Agency (study no 4574). Full protocol for this cohort study has been described elsewhere [22] .
Data Source
The source of data was the French health insurance database, named Syst eme National d'Information Inter-R egimes de l'Assurance Maladie (SNIIRAM) [23] . This database contains individualized, anonymous and linkable data. These data are prospectively recorded for every patient benefitting from health care in France, virtually covering the entire French population (66.6 million inhabitants in January 2016). They include data regarding demographics, long-term disabling diseases allowing full medical expenditure reimbursement, hospitalizations, outpatient procedures and drug dispensing. Hospitalization data include procedures, diagnosis codes (one principal, one related and unlimited associated diagnoses encoded within the International Classification of Disease, version 10 [ICD-10]) and costly drugs dispensed, such as rituximab or IVIg. Data regarding out-and in-hospital drug dispensing include the drug name, the dosage and the form, as well as the quantity delivered and the date of dispensing [23] .
Population source
The patients' selection process has been described elsewhere [7, 22] . Briefly, 2009-2012 data from patients with a long-term disabling disease encoded as ITP (ICD-10 code D69.3) and/or ≥ 1 hospital stay with a main or related diagnosis encoded as D69.3 during this period were extracted from the SNIIRAM database. The huge majority of patients (> 95%) were identified thanks to a hospital stay code corresponding to ITP [7] . These codes have demonstrated a positive predictive value of 89.8% (95% confidence interval [CI], 85.6-92.9%) and a sensitivity of 81.25% (95% CI, 56.99-93.41%) in the SNIIRAM [24] . The date of diagnosis was defined as the first diagnosis code or the first dispensing of an ITP drug before the first diagnosis code, if any. After excluding patients with ambiguous or contradictory codes suggesting miscoding (15.6%), and after exclusion of secondary ITP cases (23.0% of adult ITPs), we restricted the cohort to incident (newly diagnosed) and persistently treated patients [22] . Persistent treatment was defined as exposure to any ITP treatments exceeding three consecutive months (corticosteroids, IVIg, dapsone, danazol, thrombopoietin receptor agonists or other immunosuppressants) or to rituximab. These patients represent the population of interest from a public health point of view, as patients requiring no chronic treatment are not included in this cohort. Follow-up started at the date of first exposure to persistent treatment (entry date in the cohort) [22] . For the present study, we analyzed the sample of patients included from 1 July 2009 to 30 June 2012.
Exposures to drugs and vaccines
Exposures to drugs were considered as time-varying variables. Exposure to rituximab was considered as the 6-month period following dispensing of rituximab, because it is the usual period of complete B-cell depletion with maximal risk of infection [25] . Exposure to corticosteroids was defined as the 30 days after dispensing, in accordance with the role of corticosteroids in risk of infection assessed in this cohort and in rheumatoid arthritis [26] [27] [28] . Exposure to vaccine started from the date of dispensing. However, vaccination was considered null if it occurred within the 6 months following a rituximab infusion, because it has been demonstrated that seroconversion is severely impaired during this period in ITP patients [29] . For all other drugs, the exposure started at the date of dispensing and ended 1 month later because chronic drug are dispensed for 1 month in France.
Covariates
Covariates were age, sex, mucosal or internal bleeding at ITP onset (reflecting disease severity) [7] and co-morbidities increasing the risk or the severity of infections: diabetes mellitus and chronic cardiac, lung, kidney and liver diseases (considered separately). Co-morbidities were identified using algorithms validated in the SNIIRAM. They are based on chronic disease codes, inhospital diagnosis codes, specific procedures (i.e. hemodialysis for severe chronic kidney disease) and outof-hospital dispensing of specific drugs [30] . Of note, patients with cancer, connective tissue disease, chronic viral infection and primary immune deficiency were considered as secondary ITP patients and were not included in this cohort [7, 22] .
Outcomes
Serious infections were defined as hospitalizations with an ICD-10 code of infection as the primary diagnosis. The codes used, identified by ICD-10 review, are listed in Table S1 . In a cross-sectional study, the positive predictive value of these codes for an infection as the reason for hospitalization was 97% (95% CI, 93-100). Among the truepositive cases, the positive predictive value of correct coding of the type of infection was 98% (95% CI, 95-100) [31] .
Because diagnoses from general practitioner visits are not recorded in the SNIIRAM, non-serious infections were identified using out-of-hospital antibiotic dispensing as a proxy.
Statistical analysis
We analyzed serious infections and non-serious infections separately. Incidence rates of serious and non-serious infections and their corresponding 95% CIs were computed as the total number of first events divided by the total person-time at risk, following a Poisson distribution. Time at risk was defined as the date of entry into the cohort until the earliest date of the following: death, splenectomy, first occurrence of the event of interest (serious and non-serious infections) or end of the study (31 December 2012). The cumulative incidences of first serious and non-serious infections were calculated using the Kaplan-Meier method.
To assess the risk factors for serious infections and nonserious infections, we performed a multivariate Cox model adjusted on all covariates for each outcome (stepwise backward procedure, a = 5%). Age was considered continuous in the model assessing the risk of serious infection because the linearity hypothesis was satisfied. In contrast, it was not the case in the non-serious infection model and we used the cut-off value of 65 years that had been chosen a priori. All calculations were carried out using SAS 9.4 ™ statistical software (SAS Institute, Cary, NC, USA). 
Serious infections
Overall, 161 (9.1%) patients experienced serious infections. The incidence of serious infections was 6.3/100 patient-years (95% CI, 5.4-7.4) (Fig. 1) . Of note, 42.8% of SIs were lower respiratory tract infections and 11 were opportunistic (zoster, n = 4; pneumocystosis, n = 2; tuberculosis, n = 2; aspergillosis, n = 3). They are listed in Table S2 . Out of the 89 patients who died during the study period, three died in the month following a serious infection (two had sepsis and one had encephalitis).
Results of the multivariate model are shown in Table 2 . Increasing age, male sex, mucosal or internal bleeding at ITP onset, chronic pulmonary disease and chronic kidney disease were baseline covariates associated with occurrence of a serious infection. Among treatments, the hazard ratio (HR) for corticosteroids was 3.83 (95% CI, 2.76-5.31). The median time from first corticosteroid exposure to serious infection in patients exposed to corticosteroids at the time of serious infection was 198 days (exposure to corticosteroids may have been intermittent). The HR was 2.60 (95% CI, 1.67-4.03) for rituximab. The median time from first rituximab infusion to serious infection in patients who experienced serious infections in the 6 months following a rituximab infusion was 69 days. IVIg were also associated with a higher risk of infection (HR, 2.98; 95% CI, 1.86-4.77).
Pneumococcal vaccine showed a protective effect (HR, 0.38; 95% CI, 0.20-0.73), as did influenza vaccine (HR, 0.42; 95% CI, 0.27-0.64).
Non-serious infections
Overall, 1227 (68.0%) patients experienced a non-serious infection. The incidence was 100.5/100 patient-years (95% CI, 95.0-106.3) (Fig. 2) . Penicillins were the antibiotic drug class that was most frequently dispensed (43.8%, see Table S3 ). Out of the 89 patients who died during the study period, five died in the month following a non-serious infection.
Results of the multivariate model are shown in Table 3 . Increasing age and chronic pulmonary disease were also associated with occurrence of non-serious infection. The HR was 2.46 (95% CI, 2.19-2.76) for corticosteroids and 1.49 (95% CI, 1.28-1.74) for rituximab. The median time from first corticosteroid exposure to non-serious infection in patients exposed to corticosteroids at the time of nonserious infection was 61 days (exposure to corticosteroids may have been intermittent). The median time from first rituximab infusion to non-serious infection in patients who experienced a non-serious infection in the 6 months following a rituximab infusion was 71 days. Pneumococcal vaccine showed a protective effect for non-serious infections (HR, 0.52; 95% CI, 0.43-0.65), as did influenza vaccine (HR, 0.49; 95% CI, 0.41-0.59). IVIg were also associated with a higher risk of non-serious infection (HR, 1.76; 95% CI, 1.49-2.08).
Discussion
This study demonstrated that age and chronic lung disease were the main baseline risk factors for both serious and non-serious infection in non-splenectomized persistently treated adults with primary ITP. Male sex and lifethreatening ITP (with severe bleeding at ITP onset) were also associated with serious infection. Corticosteroid exposure was the leading drug-related risk factor for both serious and non-serious infection, followed by rituximab. Pneumococcal and influenza vaccines were associated with a ≥ 50% reduction in occurrence of serious and nonserious infection. Of note, the characteristics of the patients in terms of age and sex are in accordance with what is known of the epidemiology of ITP in adulthood in France [32] . The low number of patients with mucosal or internal bleeding at ITP onset may be due to the fact that only serious bleeding (life-threatening, requiring specific care or increasing the duration of hospital stay, such as central nervous system or gastrointestinal bleeding) is encoded in the database [7] . However, this estimate may be distributed at random regarding the other covariables, and thus may not have heavily biased their HR estimates.
The pattern of serious infection sites (mostly lung infections) was consistent with data from a Danish population-based study [12] . The pattern of out-of-hospital antibiotic dispensing is also consistent with a similar pattern of locations of non-serious infections. This probably explains why pneumococcal and influenza vaccines were associated with a reduction in the overall occurrence of serious infection and non-serious infection, a finding that requires confirmation.
Because of the experimental data [29] , we chose to consider vaccinations as null if they occurred in the 6-month period following a rituximab infusion. However, data on the clinical effectiveness of such vaccinations are lacking and specific studies with more exposed patients need to be conducted in future to address this question.
The association of IVIg with a higher risk of infection may be because of a channeling bias. Indeed, IVIg are indicated in the case of serious bleeding (according to French guidelines, in the case of Khellaf's score > 8 [4] ). This clinical score is not captured in our models, although disease severity was associated with a higher risk of serious infection. IVIg are also used off-recommendation for maintaining remissions (using monthly infusions) in about 10% of persistently treated ITP adults in France [10] . This treatment is likely to be used in frail patients who may have various co-morbidities that potentially increase the risk of infection, not captured with the main assessment of co-morbidities used in our study. Lastly, patients exposed to IVIg are by definition regularly hospitalized, which may be a risk factor for infection per se. Of note, in a case-control design study assessing the risk of SI in the same population, the number of patients exposed to IVIg was also significantly higher among the cases than among the controls. This was also the case for exposure to rituximab and corticosteroids [26] . On the other hand, one cannot fully rule out that IVIg may be associated with an increased risk of infection as a result of an immunological mechanism (e.g. by saturating FccReceptors on phagocytic cells).
Some limitations should be discussed. First, the identification of patients relied on diagnosis codes recorded in the database. Therefore, the possibility of miscoding cannot be fully ruled out. However, this seems very unlikely given the multiple precautions taken in the construction of the cohort [7, 22] : in-hospital ITP codes have a high accuracy in the SNIIRAM [24] ; patients with ambiguous or contradictory D69 codes from the study start until 6 months after the first ITP code were excluded [22] ; and the cohort is restricted to patients exposed to ITP treatment for at least 3 months. On the other hand, this cohort represents a subcategory of ITP patients, sicker than the overall ITP population. Therefore, these results are not generalizable to all ITP patients. Second, the current study includes persistently treated primary ITP adult patients. Thus, our results cannot be extended to all ITP patients. Third, we used antibiotic dispensing as a proxy for non-serious infections. This dispensing may not reflect bacterial infection and some antibiotics may have been prescribed for prophylaxis. However, the results were consistent with those for serious infections. Fourth, exposures were defined using dispensing data, which does not guarentee that the patient effectively took the drug. However, this probably allows a more accurate measure of exposure than prescription data. Fifth, we could not adjust the analyses for some clinical variables not recorded in the database, such as tobacco. Similarly, laborataory test results are not recorded in the SNIIRAM and we could not adjust for platelet count or hypogammaglobulinemia. Lastly, no association between other immunosuppressive drugs (azathioprine, mycophenolate and cyclosporine) and serious/non-serious infections was found, possibly because of the small number of patients exposed to these drugs.
In conclusion, serious infections were mainly respiratory infections in non-splenectomized adults with primary ITP who were persistently treated. Age, chronic pulmonary disease, corticosteroids and rituximab were the main risk factors for infections, whereas pneumococcal and influenza vaccines were protective against serious and non-serious infections.
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